Pharmacodynamic monitoring of immunosuppressive drugs.
Pharmacodynamic (PD) monitoring measures the biological response to a drug, which alone--or coupled with pharmacokinetics--provides a novel method for optimization of drug dosing. PD monitoring has been investigated by us and other investigators primarily for four immunosuppressive drugs: cyclosporine (CsA), azathioprine (AZA), mycophenolate mofetil (MMF), and rapamycin (RAPA). PD monitoring of CsA and MMF involves measuring the activity of the enzymes calcineurin and inosine monophosphate dehydrogenase, respectively. The PD of AZA is assessed by measuring the activity of thiopurine methyltransferase, which is induced by a metabolite of AZA, 6-mercaptopurine. The PD for RAPA involves measuring the activity of a P70 S6 kinase in lymphocytes. To date, the most detailed studies have been performed with PD monitoring of CsA and MMF. Similarities exist in the PD responses to CsA and MMF in renal-transplant patients. At trough concentrations in blood, both drugs reduce the activity of their target enzymes by only 50%; however, considerable interpatient variability is evident. Throughout the dosing interval, the enzyme activities parallel the respective drug concentrations. AZA treatment of renal-transplant patients who exhibited an increase in thiopurine methyltransferase activity from time of transplantation resulted in fewer episodes of active rejection. Additional clinical trials are currently underway to relate various pharmacokinetics and PD parameters to clinical response, to ascertain which provides the best guide for dosing. PD monitoring may provide an alternative approach to additional measurements of drug concentrations.
Yatscoff
R W
RW
Isotechnika Inc., Edmonton, AB, Canada.
Aspeslet
L J
LJ
Gallant
H L
HL
D001379:Azathioprine / Q000097:blood / Q000627:therapeutic use; D019703:Calcineurin / Q000032:analysis / Q000097:blood; D016572:Cyclosporine / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D016903:Drug Monitoring; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D007168:IMP Dehydrogenase / Q000032:analysis / Q000097:blood; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008780:Methyltransferases / Q000032:analysis / Q000097:blood; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D011090:Polyenes / Q000494:pharmacology / Q000627:therapeutic use; D019893:Ribosomal Protein S6 Kinases / Q000032:analysis / Q000097:blood; D020123:Sirolimus
D007166:Immunosuppressive Agents; D011090:Polyenes; D016572:Cyclosporine; D007168:IMP Dehydrogenase; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D019893:Ribosomal Protein S6 Kinases; D019703:Calcineurin; D009173:Mycophenolic Acid; D001379:Azathioprine; D020123:Sirolimus